Eledon pharmaceuticals reports fourth quarter and full-year 2020 operating and financial results

Continued enrollment in phase 2 clinical trial of at-1501 in amyotrophic lateral sclerosis (als)
ELDN Ratings Summary
ELDN Quant Ranking